ARV-based HIV Prevention Product Introduction and Access

The **who** (implementing partners) and **what** (objective) of the five US Agency for International Development’s (USAID) Office of HIV/AIDS Microbicide Product Introduction Initiative (MPii) agreements, from 2015 to 2020, on ARV-based HIV prevention product introduction and access.

**INTRODUCTION & ACCESS PROCESS**

**OPTIONS**

- **Optimizing Prevention Technology Introduction On Schedule**
  - **Who:** FHI 360, Wits RHI, AVAC
  - **What:** Provide targeted support to expedite and sustain access to ARV-based HIV prevention products in countries and among populations where most needed.

- **Enhancing Microbicide Uptake in High-risk End Users**
  - **Who:** CONRAD
  - **What:** Increase uptake and correct and consistent use of ARV-based HIV prevention products by women at high risk of HIV infection using an end-user centered strategy.

- **Global Evaluation of Microbicide Sensitivity**
  - **Who:** University of Pittsburgh
  - **What:** Inform policies and define programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance.

- **Community: Health clinical model for Agency in Relationships and Safer Microbicide Adherence**
  - **Who:** RTI International
  - **What:** Support women’s agency to safely use ARV-based HIV-prevention products and reduce vulnerability to intimate partner violence.

**POWER**

- **Prevention Options for Women Evaluation Research**
  - **Who:** University of Washington
  - **What:** Develop cost-effective and scalable models for implementation of ARV-based HIV prevention products for women.

- **GEMS**
  - **Research, modeling and policy on risk of resistance**

**EMOTION**

- **Market and end-user research**
  - **Who:** University of Pittsburgh
  - **What:** Provide targeted support to expedite and sustain access to ARV-based HIV prevention products in countries and among populations where most needed.

**CHARISMA**

- **Women’s agency and partner interventions**
  - **Who:** University of Washington
  - **What:** Develop cost-effective and scalable models for implementation of ARV-based HIV prevention products for women.

---

November 2015